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Abstract 
 
Candida albicans and Pseudomonas aeruginosa are two of the most common healthcare related 
diseases today. Candida is ranked the 4th most common cause of over 46,000 healthcare associated 
bloodstream infections (CDC, 2013). Pseudomonas causes 51,000 healthcare related infections in 
both the bloodstream and at surgical sites (CDC, 2013). Due to their ability to form infect ious 
biofilms on biotic and abiotic surfaces, they are rapidly becoming antibiotic resistance over time. 
With very few new drugs manufactured each year, only 13 in 2014 (CDC), these infections pose 
serious public health threats. Alternative treatments are urgent.  Filastatin is a small molecule that 
exhibits inhibitory properties when applied to Candida albicans. It is shown to inhibit the adhesion 
and filamentation of the fungus to abiotic surfaces.  Growth phases of C. albicans and P. 
aeruginosa when exposed to Filastatin were examined to identify any effects on microbia l 
formation.  Results indicated that Filastatin does disrupt the initial growth of both C. albicans and 
P. aeruginosa.  
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Introduction 
In 2013, the CDC ranked Candida albicans and Pseudomonas aeruginosa as serious 
antibiotic resistant threats. Candida is ranked the 4th most common cause of over 46,000 healthcare 
associated bloodstream infections (CDC, 2013). Pseudomonas causes 51,000 healthcare related 
infections in both the bloodstream and at surgical sites (CDC, 2013). From 1998-2003, a 56% 
decrease in new FDA approved drugs was observed (Spellberg B, 2004). In 2014, only 13 were 
discovered and approved. Overall, this is a growing problem as both C. albicans and P. aeruginosa 
are becoming resistant to the available drugs. With the small amount of new drugs reaching the 
market each year, this problem worsens thus the need for antifungal and antibacterial agents is 
urgent (Conly, 2005). 
The first prevalent pathogen is Candida albicans, a common dimorphic fungus known to 
naturally live in the gastrointestinal tract, mouth, epithelial lining, and genital tract of humans 
without highly negative effects. As seen in Figure 1 this fungus possesses two morphologica l 
features: oval (blastospore) and filament. The yeast form, or blastospore, of the fungus grow at 
low pH and typically bud off of the hyphal nodes when in pseudohyphae form (Kadosh, 2005). 
The filament shape can survive a variety of pH levels and are constricted by the groups of 
blastospores. If the fungus enters hyphae form these constrictions are absent allowing unbroken 
elongated cells that are predicted to be much more invasive populate (Saville, 2003). In order for 
the fungus to be infectious, free switching between the pseudohyphae and hyphae form is required 
(Saville, 2003). 
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Figure 1: Commensal C. albicans Structure (CDC, 2013) 
 
C. albicans is known to be dimorphic in that it switches between the two structures 
depending on environmental conditions. The transition from blastospore to filament can occur at 
elevated body temperatures (37°C) and in the presence of serum or certain human hormones 
(Kadosh, 2005). When a patient’s immune system is compromised, the environment in which the 
fungus naturally occurs changes to a set of ideal conditions for the morphological transition. This 
enables C. albicans to more commonly undergo hyphae growth where more filament forms are 
made. These shapes are required for deep-seated infection as they are better suited for penetrating 
the mammalian host tissue but the transition in which they are formed is required for init ia l 
virulence (Liu, 2004).  
This transition is known to induce 61 genes in response to higher temperature and/or 
presence of serum. About half of these are transcriptionally repressed when in the blastospore 
shape by Rfg1, Nrg1, and Tup1 (Kadosh, 2005). In order to determine if these genes that induce 
filament formation are the initial cause of virulence, an engineered strain containing Nrg1 and a 
tetracycline promoter was done in 2003. When mice were injected with the strain and exposed to 
the ideal conditions for blastospore-filament transition, infection and mortality was observed. 
When placed under normal, non-immunocompromised conditions mortality was not observed. 
This indicated that the morphogenetic conversion that leads to the activation of multiple genes that 
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leads to the growth of continuous filaments is necessary for the pathogenesis of C. albicans 
(Saville, 2003).  
Not only does the morphological plasticity of this fungus pose a problem if environmenta l 
changes are common but the strongest set of hyphal transition filament that leads to virulence 
includes heightened body temperature and serum, such as blood (Ernst, 2000). These are common 
in a healthcare setting as the patient is fighting infection as well as exposed to many instruments 
that can come in contact with bodily fluids such as blood. 
Biofilms of C. albicans are the most likely to come in contact with bodily fluids and further 
grow due to an ideal environment. The morphological plasticity of C. albicans also enables it to 
be highly resilient when a biofilm is formed. Biofilms are a large group of cells that adhere to a 
biotic or abiotic surface and grow to form an extracellular matrix (ECM). A biofilm can be 
compared to a blister where the outside is tough and protects the inside. Cell density is greatest at 
the base and inside of a biofilm leading to an extremely thick mass of cells embedded in the ECM 
as seen in Figure 2 (Ganguly, 2011). The ECM is known to contain host immune cells called 
neutrophils. Neutrophils can adsorb many things including antibiotics thus preventing the lower 
layers of the biofilm from being harmed (Ganguly, 2011). This physical characteristic alone causes 
the biofilm to be nearly impenetrable (Ganguly, 2011).  
 
Figure 2: C. albicans Biofilm Structure (hindawi) 
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Not only does this complex ECM layer of a biofilm protect the inside but it produces two 
components that make it infectious: Farnesol and Tyrosol. Farnesol is an inhibitor of hyphal 
formation while Tyrosol is a stimulator. Although these two molecules counteract each other, as 
cell density of a biofilm increases the production of Tyrosol becomes greater than Farnesol leading 
to the infectious pseudohyphae-hyphae transition of the many embedded yeast and filamentous 
cells found in the ECM (Finkel, 2010). Thus the production of more infectious filament structures 
occurs (Finkel, 2010). The more a biofilm grows the thicker it becomes making it more drug 
resistant. The thicker it becomes the more it irreversibly adheres to the surface. The more cell 
density increases the more Tyrosol is produced causing it undergo the transition that makes it 
infectious. Because of this, biofilms pose a large problem in a medical setting as they can appear 
on many things such as catheters and implants that come in contact with bodily fluids (Finkel, 
2010). As long as it is a solid surface, bacteria and fungus alike are able to stick to it and grow. 
Not only are biofilms impenetrable, drug resistant infectious masses, but they have been 
shown to prevent the activation of reactive oxygen species (Xie, 2012). ROS are compounds 
produced by an enzyme called NADPH oxidase found in phagocytic cells. If a pathogen is 
recognized by the system, this complex is assembled within the phagocytic membrane and allowed 
to react with superoxide radicals. Once reacted, hydrogen peroxide is produced and transported 
into the neutrophil within the phagocyte (Edens, 2001). This creates an antibacterial or antifunga l 
environment within the phagocyte leading to eventual cell death (Edens, 2001). Because C. 
albicans biofilms are known to reduce the production of ROS, this antimicrobial environment is 
no longer created thus phagocytes are no longer killed. If they are not killed they are able to recruit 
others and further infect a patient. 
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Because of these many properties, C. albicans is able to infect all major organs and tissues 
of the human body (Saville, 2003). When placed in a healthcare setting where biofilm formation 
is common and come in contact with an environmental niche for hyphal growth, C. albicans 
quickly becomes a well-supported newly infectious pathogen. 
 It is clear that C. albicans poses a large problem regarding medical related infections. With 
a 30% mortality rate related to medical devices since 2004, an antifungal solution is necessary 
(Kojic, 2004).  
The second pathogen, Pseudomonas aeruginosa is said to range from 18% to 61% 
mortality rates with an 87.8% antibiotic resistance in 2008 (Kang, 2003; Vitkauskienė, 2011) 
making it another large issue in the healthcare field. This gram-negative bacteria is problematic 
for patients with cystic fibrosis, immunocompromised systems, and with burn injuries. Due to the 
structure of P. aeruginosa as seen in Figure 3, it’s able to attach to a variety of surfaces and interact 
with the host (Ivanov, 2010). 
 
Figure 3: P. aeruginosa Structure (CDC, 2013) 
Pseudomonas aeruginosa consists of lipopolysaccharides (LPS) in the outer layer of the 
cell. LPS contains lipid A that anchors it to the outer membrane, a core oligosaccharide, and sugar 
side chains such as O-antigens and H-antigens (Ivanov, 2010). The O-antigen side chain consists 
of repeating saccharide units that impart serospecificity and protrude into the surrounding 
environment as seen in Figure 3 (Ivanov, 2010). These long side chains enable the bacteria to 
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interact with its surroundings and contribute to its adhesion ability (Ivanov, 2010). P. aeruginosa 
also consists of an H-antigen which is a single flagella at the base of the structure allowing it move 
across surfaces it may adhere to (Stanislavsky, 1997). 
Although this bacteria consists of an extremely invasive physical structure, it has been 
shown that the O-antigen is required for virulence (Ivanov, 2010). Without the long sugar chain 
protruding into the environment, less adhesion to epithelial cells can occur (Tang, 1996). Similar 
to C. albicans, P. aeruginosa is still viable if part of its structure is missing. In C. albicans, filament 
forms are not required for viability. In P. aeruginosa, O-antigens are not required for viability 
either (Kintz, 2008). 
As mentioned, it has been shown that the O-antigen is required for bacterial virulence. This 
is not the case regarding Cystic Fibrosis patients making this type of infection even more 
complicated. When a patient has cystic fibrosis, epithelial cells express a delta F508 alelle in the 
cystic fibrosis transmembrane conductance regulator or CFTR (Pier, 1996). This expression in 
CFTR causes the cells to be defective in uptake of P. aeruginosa as it only ingests the core-
oligosaccharide (Pier, 1996). Knowing that bacterial virulence requires the uptake of the O-antigen 
side chain, one would think that this defect would protect the epithelial cells from infect ion. 
Instead, an increase in bacterial accumulation in the lungs of cystic fibrosis patients is observed 
(Pier, 1996). It is inferred that this allele expression in CFTR contributes to the virulence of P. 
aeruginosa (Pier, 1996). This interaction poses an even larger problem in the medical field as one 
infection is able to make another express bacterial virulence. 
Patients without cystic fibrosis such as immunocompromised or burn victims have not 
shown these types of interactions. The O-antigen appears to still be required for bacterial virulence. 
Because these sugar chains consist of saccharide units, they can vary in length thus vary in 
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virulence (Ivanov, 2010). The longer the sugar chain, the more units can interact and bind to 
surrounding surfaces. It has been shown that these O-antigens can change in length depending on 
the surface it initially adheres to (Ivanov, 2010). Such an ability allows P. aeruginosa to not only 
interact with a variety of surfaces but effectively adhere to many of them through variation in its 
O-antigens (Ivanov, 2010). 
Similarly to C. albicans, P. aeruginosa is able to form biofilms on various surfaces due to 
interactive structure. Biofilm formation depends on quorum sensing or QS between the cells on a 
surface such as glass. When cell density of a formation of cells is high enough, QS induces the 
production of acylated homoserine lactones (Schaber, 2007). When these AHLs are produced in a 
P. aeruginosa biofilm, they are able to bind and regulate the activity of transcription factors LasR 
and RhlR. These two factors are then able to transcribe multiple genes that can produce toxins that 
lead to the virulence of the bacterial biofilm (Schaber, 2007). Biofilm formation not only begins 
with antigens shown to cause virulence adhering to a surface but also increases in virulence due to 
a cascade effect as a result of quorum sensing (Schaber, 2007). In the medical field where biofilm 
formation is common, this is a large threat. 
These antigens are extremely effective for the bacterial virulence, antibiotic resistance, and 
biofilm formation of P. aeruginosa but also exhibit some beneficial properties. O-antigens and the 
H-antigen are highly immunogenic (Stanislavsky, 1997). Among these antigens is a mucoid 
substance on the surface of the bacteria that contain unique epitopes. When these epitopes are 
found in the antigens, cross-protective immunity against P. aeruginosa is observed indicating a 
potential vaccine application (Stanislavsky, 1997). When injecting a vaccine containing these 
epitopes at low masses of 20 to 100kDa into human volunteers, high levels of antibodies against 
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P. aeruginosa were found (Stanislavsky, 1997). Plasma containing these antibodies helped recover 
87% of patients with severe forms of P. aeruginosa.  
These results indicate that not only does the structure lead the bacteria to be extremely 
invasive, but it can be used to treat P. aeruginosa as well. Because P. aeruginosa is a serious 
medically related infection (CDC, 2013), all avenues for treatment should be explored. A vaccine 
using the very antigen that makes it infectious has shown promising signs but the goal is to prevent 
the infection entirely thus the need for an antibacterial treatment is necessary. 
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Materials and Methods 
Strains 
 In all experiments, the medically common strain used for C. albicans was CS 5314. The 
strain used for P. aeruginosa was PAO1 F173. Both strains were kindly provided by Professor 
Reeta Prusty Rao, Worcester Polytechnic Institute and kept at -4°C for later use. When needed, 
samples were taken from original supply and grown in fresh media to ensure viable cells. 
 
Establishment of Optical Density vs. Cell Concentration Correlation 
All strains were maintained in tryptic soy broth (TSB). 30 µl of C. albicans CS 5314 from 
overnight culture in TSB was added to 30 ml of fresh TSB medium in the 25 ml Falcon® tissue 
culture flask (Becton Dickinson, Franklin Lakes, NJ). This was incubated on a Glas-Col 099A-
RD4512 Rotator (Terre Haute, IN) at 37 ˚C.  2 ml of sample from the container was taken at 
different time points such as 0 hour, 3 hour, 6 hour, etc. and its optical density was measured by 
using Evolution 300 UV-visible spectrophotometer (Thermo Scientific).  The data obtained was 
processed using Microsoft Excel 2013 to identify a time point at which C. albicans growth reaches 
1 O.D. at 600 nm. This process was repeated using P. aeruginosa. Up to three additional trials 
were carried out to establish data consistency. 
To examine the effects of Filastatin on the growth of both C. albicans and P. aeruginosa, 
12.5 µM of Filastatin was added to the same mixture described earlier. 2 ml of sample from the 
container was taken at different time points such as 0 hour, 3 hour, 6 hour, etc. and its optical 
density was measured by using Evolution 300 UV-visible spectrophotometer (Thermo Scientific).  
The data obtained was processed using Microsoft Excel 2013 to identify any changes in growth 
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time of C. albicans when in the presence of Filastatin. This process was repeated using P. 
aeruginosa. Up to three additional trials were carried out to establish data consistency. 
 To determine a cell concentration curve in reference to incubation time, 200 µl of the 2 ml 
samples taken during each of the four growth curves was loaded into a Bright Line® 
hemacytometer (Reichert, Buffalo, NY) for cell counting. Using a microscope at 40X, the four 
corner squares of the outside perimeter as well as center square were used to count cells. 10-fold 
serial dilutions using TSB were required at times if cell density was too high. An average number 
of cells per square taken by dividing the total by 5. By multiplying the resulting number by the 
dilution factor of the sample and concentration of 104, a final cell number per mL was determined. 
These results were plotted in comparison to incubation time and corresponding OD data. Because 
OD and cell concentration now share the same x values, a plot of OD vs. cell concentration can be 
made. By fitting a linear trend line to the data, a correlation equation was determined. Due to the 
small size and mobility of P. aeruginosa, it was not counted by hand using a hemacytometer. 
Instead a literature correlation was used (Kim, 2012). Ideally, growing the 2 ml sample taken at 
each time point could have been plated on Tryptic Soy Agar, incubated at 27°C overnight, and 
colonies hand counted. 
 
Biofilm Growth and Bioreactor Experiment 
 3x104 cells/ml of C. albicans CS 5314 in 1L TSB was kept at 0 ˚ C and was allowed to flow 
on (3-aminopropyl)-trimethoxylsilane (APTMS) and bare glass surfaces in the bioreactor. APTMS 
prevents the adsorption of small organic molecules to the glass surface while increasing the 
number of bonds between them (Seed, 2003). Because of this a larger amount of biofilm was 
expected on the APTMS coated glass coupons. The system was run using a Manostat Carter 
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Cassette Pump (Barnant Company, Barrington, IL) at a flow rate of 329 µL/min to simulate 
physiological flow. This helps represent bloodstream infections where both C. albicans and P. 
aeruginosa are able to spread throughout the body. Both bioreactors were then placed in a 37˚C 
water bath to simulate the slightly higher body temperature of an immunocompromised system 
that is ideal for both C. albicans and P. aeruginosa biofilm formation. The system was run for 17 
hours or until the mixture was gone.  
 
Crystal Violet Adhesion Assay Staining and Analysis 
After 17 hours of incubation, glass coupons were removed from the bioreactors and stained 
with 0.3 ml of Gram crystal violet (Becton Dickinson, Franklin Lakes, NJ) for 15 minutes.  The 
crystal violet stain was carefully removed using a micropipetter and the surface was rinsed gently 
3 times with Phosphate-Buffered Saline to remove any extra stain.  Biofilm was dissolved in 0.5 
ml of 33% (v/v) acetic acid.  The optical density of the dissolved biofilm was quantified using a 
Victor3 1420 multilabel reader (Perkin-Elmer, Waltham, MA) at 590 nm.  The data obtained was 
processed by using Microsoft Excel 2013 to identify how much biofilm formed on each coupon. 
This process was repeated using P. aeruginosa. Data was processed using Microsoft Excel 2013 
to determine the cell concentration of the biofilms formed on each coupon.  
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Results 
Establishment of Optical Density vs. Cell Concentration Correlation 
 The goal of this project is to determine the effects on cell concentration of C. albicans and 
P. aeruginosa that Filastatin may have. To achieve this, a method for determining cell 
concentration is needed. Growth curves for C. albicans, C. albicans + Filastatin, P. aeruginosa, 
P. aeruginosa + Filastatin were established over 24 hours in Tryptic Soy Broth media.  
2 ml samples were collected, an optical density reading obtained using a spectrometer, and 
a cell count performed using a hemacytometer. By plotting incubation time versus OD or cell 
concentration, growth curves of C. albicans could be established as seen in Figure 14 and Figure 
15 in Appendix A. Using Microsoft Excel 2013, a plot of OD versus cell count could then be 
generated as seen in Figure 4. An equation relating OD and cell concentration could then be found 
by fitting a linear trend line to the data. Summary tables of calculations relating to Figure 14 and 
Figure 15 can be found in the Appendix B. Multiple trials were performed to ensure consistent 
results.  
 
Figure 4: C. albicans OD at 600nm vs. Cell Concentration in cells/ml 
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Optical density for P. aeruginosa was determined using the same process as for C. albicans 
and plotted in Figure 16 in Appendix A. Cell concentration could not be determined using the cell 
counting and hemacytometer method. Due to the mobility and morphological properties of this 
bacteria, it was impossible to count the number of cells in each time sample using a 
hemacytometer. A flow cytometer could not be used either as the flagella tail on P. aeruginosa 
allows it to move in all directions. This would cause the flow cytometer to potentially read the 
same cell twice if it were to move in the reverse direction past the sensor. A literature correlation 
for optical density versus cell concentration was found instead (Kim, 2012). In this technique they 
plated 100 µl of samples taken at various time points, grew them over night, and counted the 
colonies that formed. This was attempted however Tryptic Soy Agar did not settle well enough for 
the sample to grow. In order to move forward, the equation provided by the correlation was used 
to determine the cell concentrations at the experimentally collected optical density values and 
plotted (Figure 17 in Appendix A).  Summary tables of calculations relating to Figure 16 and 
Figure 17 can be found in Appendix B. Multiple trials were performed to ensure data consistency. 
Some error was observed and will be discussed in a later section. 
 In order to observe the effects Filastatin has on the cell concentration of both C. albicans 
and P. aeruginosa, growth curves using 12.5 µM Filastatin and 3x104 cells/ml were generated for 
a 24 hour period in Tryptic Soy Broth media. Optical density versus incubation time can be seen 
in Figure 5 and Figure 6 below. Due to a minimal amount of available Filastatin, one trial was 
conducted for each strain. Because of this adjustment, a control using just the fungus or bacteria 
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was grown simultaneously to ensure the strain was behaving similarly to the previous data. 
Summary tables of calculations relating to Figure 5 and Figure 6 can be found in Appendix B.  
 
Figure 5: C. albicans + Filastatin Optical Density at 600nm vs. Incubation Time in hours 
 
Figure 6: P. aeruginosa + Filastatin Optical Density at 600nm vs. Incubation Time in hours 
 
 Using the OD Cell Correlation Equation for C. albicans in Figure 4 and the literature 
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results are illustrated in Figure 7 and Figure 8 below with summary tables of calculations in 
Appendix B.  
 
Figure 7: C. albicans vs. C. albicans + Filastatin Cell Concentration cells/ml 
 
Figure 8: P. aeruginosa vs. P. aeruginosa + Filastatin Cell Concentration cells/ml 
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Quantitation of Biofilm Growth using Crystal Violet Adhesion Assay 
 To better understand biofilm formation of C. albicans and P. aeruginosa, biofilm growth 
experiments were conducted. These trials consisted of circulating 3*104 cells/ml in 1L of TSB of 
either C. albicans or P. aeruginosa through a bioreactor containing 5 glass coupons under 
physiological flow. The coupons were either bare glass or coated with APTMS and placed in 
separate bioreactors. The experiments were run for about 17 hours to ensure that the fungus or 
bacteria completed all three growth phases established by the growth curve data. The glass coupons 
were then removed from the bioreactor and analyzed using the Crystal Violet Adhesion Assay 
outlined in Materials and Methods. Using Microsoft Excel 2013, OD values generated by the assay 
were tabulated and plotted against the coupon number (1 through 5 with 1 being at the inlet of the 
bioreactor). Due to the nature of the crystal violet stain, a threshold for OD was set at 0.05. 
Anything below this may be due to the buffer used to wash the coupons or any residual media. 
These plots can be seen in Figure 18 and Figure 19 in Appendix A along with average OD values 
in Figure 9 and Figure 10 below. Multiple trials were conducted to ensure data consistency. 
Summary tables of calculations relating to each figure can be seen in the Appendix B. 
 
Figure 9: C. albicans Average Optical Density at 590nm in Bioreactor 
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Figure 10: P. aeruginosa Average Optical Density at 590nm in Bioreactor 
 
Using the previously determined OD vs. Cell Concentration correlation equations, cell 
concentration on each coupon was calculated. These values were plotted against the coupon 
number again as seen in Figure 20 in Appendix A with average concentration values in Figure 11. 
Because the concentration of P. aeruginosa was mostly below the set baseline as seen in Figure 9 
cell concentration values were not calculated. 
 
Figure 11: C. albicans Average Cell Concentration in cells/ml in Bioreactor 
 
Morphology Analysis 
To further investigate the effects Filastatin may have on C. albicans, a 200 µl sample of at 
its peak time was placed onto a hemacytometer during the growth curve with Filastatin (Figure 5). 
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As seen in Figure 12 and Figure 13 below, Filastatin has a huge effect on the morphologica l 
features of C. albicans. 
 
Figure 12: C. albicans at 12hrs in TSB 
 
Figure 13: C. albicans + Filastatin at 12hrs in TSB 
 In Figure 12, the long infectious filament structure of C. albicans can be seen. This was 
expected as over time, C. albicans undergoes the structural transition from yeast to filament. In 
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Figure 13, no filament forms can be seen. This indicates that when Filastatin is grown with the 
fungus, C. albicans does not undergo the blastospore-filament transition known to induce 
virulence.  
Discussion 
 
 The results of this project have shown that Filastatin does have an effect on the growth of 
both Candida albicans and Pseudomonas aeruginosa. As mentioned, bacteria and fungus possess 
different properties that give them unique infectious characteristics. C. albicans is an oval shaped 
fungus that undergoes phenotypic switching allowing for a rod shaped morphology to form. It is 
believed this hyphae filament form allows the fungus to penetrate and infect. When commensa l, 
these hyphae rod forms are connected by oval nodes as seen in Figure 1.  P. aeruginosa is a rod 
shaped bacterium with 1 polar flagellum as seen in Figure 3 allowing it to move around and 
multiply quickly. As seen in the growth curve data, Filastatin shows some inhibitory effects on 
both C. albicans (Figure 5) and P. aeruginosa (Figure 6). C. albicans reaches a growth doubling 
time at about 5 hours normally as seen in Figure 14 and Figure 15Error! Reference source not 
found. in Appendix A. When grown with 12.5 µM of Filastatin, this phase is not reached until 7 
hours as labelled in Figure 5. P. aeruginosa reaches this growth doubling time much earlier at 
about 2 hours as seen in Figure 16 and Figure 17. When grown with 12.5 µM of Filastatin the 
same phase is reached about 2 hours later at 4 hours similarly to C. albicans (Figure 6). As 
illustrated in Figure 7 and Figure 8, Filastatin shows initial inhibitory effects but both the fungus 
and bacteria reach the same exponential doubling time eventually. This indicates that Filastatin 
does effect both C. albicans and P. aeruginosa in the desired way, inhibitory, but may not be a 
solution for elimination of the strain. Both C. albicans and P. aeruginosa appear to overcome the 
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Filastatin and eventually still grow to its full potential. Higher concentrations of Filastatin may be 
necessary to observe stronger inhibitory growth effects or no growth at all. 
 When reviewing the data from the crystal violet adhesion assay for biofilm formation, clear 
differences in the ability of C. albicans and P. aeruginosa to attach to the glass coupons was 
observed. APTMS prevents the adsorption of small organic molecules to the glass surface while 
increasing the number of bonds between them (Seed, 2003). Because of this a larger amount of 
biofilm was expected on the APTMS coated glass coupons and was observed in all results. C. 
albicans Biofilm formation appeared normal when performing the bioreactor experiments as seen 
in Figure 18 and Figure 20. Trial 1 OD and cell concentration values were much less than Trial 2. 
This was because the first trial used a strain directly thawed from the freezer, which may not have 
been 100% heathy fungus. The second trial used a strain grown in TSB for 24 hours first, making 
it a healthier sample in comparison. Average values were taken of optical density and cell 
concentration as seen in Figure 9 and Figure 11. Standard deviation between the APTMS and Bare 
Glass coupons was calculated and added as error bars. The difference between APTMS and Bare 
Glass is very clear in these figures. Because APTMS binds more biofilm (Seed, 2003), bare glass 
coupons could be excluded for the remaining experiments. Bioreactor data for P. aeruginosa was 
inconclusive as seen in Figure 19 and Figure 10. This is because the optical density of each 
coupon, with the exception of the first one, was below 0.05 making it below the set threshold. Such 
a small OD could be crystal violet binding to something other than bacteria or even just the stain 
resulting in a reading at 590nm. P. aeruginosa is a very small molecule in comparison to C. 
albicans. It most likely entered the bioreactor and exited without having an opportunity to settle 
onto a glass coupon. Decreasing the flow to increase the chances it has to settle on a coupon would 
lead to unrealistic results as simulating physiological flow to relate to bloodstream infections is 
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highly important. Increasing the initial concentration of P. aeruginosa is however an option as this 
could also increase the chances of cells attaching to the coupons and should be further explored.   
Based on the results seen in Figure 5, Figure 6, Figure 12, and Figure 13, it can be 
concluded that Filastatin does inhibit the initial growth of C. albicans and P. aeruginosa. To 
further investigate the applications Filastatin can have on this fungus and bacteria, higher 
concentrations of the drug should be tested to determine if it simply delays the growth or can 
prevent it. If Filastatin is able to prevent the growth of both C. albicans and P. aeruginosa, it can 
be used to pre-treat medical devices or implants. Because Filastatin may be used to prevent 
infection within the body, a safe concentration for humans must also be determined. 
Although the leading problem surrounding C. albicans and P. aeruginosa is medical 
related infections, Filastatin shows promising effects regarding biofilm formation of C. albicans. 
As observed, C. albicans is able to form a biofilm on glass coupons in a bioreactor. It was also 
identified that Filastatin inhibits the formation of filaments indicating that the pseudohyphae -
hyphae transition that leads to infection may also be inhibited. Based on these conclusions 
Filastatin could be used as a mediator in many areas to prevent naturally occurring C. albicans 
from becoming infectious when forming biofilms on various surfaces, instruments, or implants. If 
Filastatin is proven to prevent growth when using higher concentrations, it may also prevent 
biofilm formation entirely and could be used as a pre-treatment for a variety of surfaces. These 
results bring us one step closer to understanding the effects Filastatin has on the growth of C. 
albicans and P. aeruginosa. With further exploration, Filastatin is even closer to implementa t ion 
and decreasing the threatening statistics of medical related infections. 
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Appendix A 
 
 
Figure 14: C. albicans OD at 600nm vs. Incubation Time in hours 
 
Figure 15: C. albicans Cell Concentration in cells/ml vs. Incubation Time in hours 
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Figure 16: P. aeruginosa OD at 600nm vs. Incubation Time in hours 
 
Figure 17: P. aeruginosa Cell Concentration in cells/ml vs. Incubation Time in hours 
 
Figure 18: C. albicans Optical Density at 590nm vs. Coupon Number in Bioreactor 
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Figure 19: P. aeruginosa Optical Density at 590nm vs. Coupon Number in Bioreactor 
 
Figure 20: C. albicans Cell Concentration in cells/ml vs. Coupon Number in Bioreactor 
 
Appendix B 
Figure 14 Related: 
C. albicans Trial 1 Growth Curve 5.23.2014 
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9 0.650 
10 1.053 
11 1.513 
12 1.742 
13 1.878 
14 2.015 
24 2.223 
25 2.228 
27 2.182 
C. albicans Trial 2 Growth Curve 6.4.2014 
Incubation Time (hr) OD Reading (600nm) 
0 0.000 
2 0.010 
5 0.057 
6 0.101 
8 0.260 
9 0.734 
10 1.280 
11 1.540 
12 1.702 
13 1.927 
14 2.162 
24 2.485 
25 2.396 
C. albicans Trial 3 Growth Curve 6.26.2014 
Incubation Time (hr) OD Reading (600nm) 
0 0.015 
2 0.035 
3 0.025 
6 0.101 
8 0.376 
9 0.648 
10 1.088 
11 1.248 
12 1.517 
13 1.827 
14 1.962 
24 2.266 
25 2.289 
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Figure 15 Related: 
C .albicans Cell Counting using Trial 1 Sample 5.23.2014 
Incubation Time 
(hr) 
Cell 
Count 
Average 
#cells/square 
Dilution 
Factor 
Concentration 
(cells/mL) 
0 0 0 1 0.000E+00 
3 5 1 1 1.000E+04 
6 71 14.2 1 1.420E+05 
7 158 31.6 1 3.160E+05 
8 526 105.2 1 1.052E+06 
9 229 45.8 10 4.580E+06 
10 80 16 100 1.600E+07 
11 91 18.2 100 1.820E+07 
12 104 20.8 100 2.080E+07 
13 113 22.6 100 2.260E+07 
14 152 30.4 100 3.040E+07 
24 202 40.4 100 4.040E+07 
25 199 39.8 100 3.980E+07 
27 203 40.6 100 4.060E+07 
C. albicans Cell Counting using Trial 2 Sample 6.4.2014 
Incubation Time 
(hr) 
Cell 
Count 
Average 
#cells/square 
Dilution 
Factor 
Concentration 
(cells/mL) 
0 0 0 1 0.000E+00 
2 4 0.8 1 8.000E+03 
5 69 13.8 1 1.380E+05 
6 156 31.2 1 3.120E+05 
8 531 106.2 1 1.062E+06 
9 233 46.6 10 4.660E+06 
10 73 14.6 100 1.460E+07 
11 96 19.2 100 1.920E+07 
12 108 21.6 100 2.160E+07 
13 126 25.2 100 2.520E+07 
14 141 28.2 100 2.820E+07 
24 201 40.2 100 4.020E+07 
25 198 39.6 100 3.960E+07 
C. albicans Cell Counting using Trial 3 Sample 6.26.2014 
Incubation Time 
(hr) 
Cell 
Count 
Average 
#cells/square 
Dilution 
Factor 
Concentration 
(cells/mL) 
0 6 1.2 1 1.200E+04 
2 38 7.6 1 7.600E+04 
3 32 6.4 1 6.400E+04 
6 167 33.4 1 3.340E+05 
8 193 38.6 10 3.860E+06 
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9 222 44.4 10 4.440E+06 
10 51 10.2 100 1.020E+07 
11 67 13.4 100 1.340E+07 
12 89 17.8 100 1.780E+07 
13 121 24.2 100 2.420E+07 
14 155 31 100 3.100E+07 
24 182 36.4 100 3.640E+07 
25 179 35.8 100 3.580E+07 
 
Figure 16 Related: 
P. aeruginosa Trial 1 Growth Curve 6.4.2014 
Incubation Time (hr) OD Reading (600nm) 
0 0.001 
2 0.013 
4 0.157 
5 0.556 
6 1.035 
8 1.466 
9 1.815 
10 2.03 
11 2.131 
21 2.595 
23 2.673 
25 2.766 
  
P. aeruginosa Trial 2 Growth Curve 6.26.2014 
Incubation Time (hr) OD Reading (600nm) 
0 0.018 
2 0.019 
3 0.020 
4 0.021 
5 0.023 
6 0.033 
7 0.062 
8 0.210 
9 0.475 
10 1.146 
11 0.646 
21 2.513 
24 2.722 
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P. aeruginosa Trial 3 Growth Curve 6.26.2014 
Incubation Time (hr) OD Reading (600nm) 
0 0.015 
2 0.018 
3 0.020 
4 0.024 
5 0.045 
6 0.175 
7 0.405 
8 0.990 
9 1.299 
10 1.170 
11 1.135 
21 2.408 
24 2.611 
  
P. aeruginosa Trial 4 Growth Curve 7.3.2014 
Incubation Time (hr) OD Reading (600nm) 
0 -0.359 
2 0.001 
4 0.265 
5 0.583 
6 0.773 
7 0.966 
8 1.132 
18 1.575 
24 1.857 
26 2.016 
 
Figure 17 Related: 
P. aeruginosa Cell Concentration OD Correlation 
using equation y = 2E+8x+4E+6 
Optical Density (600nm) Cell Concentration (cell/mL) 
0.0 4.00E+06 
0.2 4.40E+07 
0.4 8.40E+07 
0.6 1.24E+08 
0.8 1.64E+08 
1.0 2.04E+08 
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1.2 2.44E+08 
1.4 2.84E+08 
1.6 3.24E+08 
1.8 3.64E+08 
2 4.04E+08 
2.2 4.44E+08 
2.4 4.84E+08 
2.6 5.24E+08 
 
P.aeruginosa Cell Counting using Trial 1 Sample & y = 2E+8x+4E+6 
Incubation Time (hr) Optical Density (600nm) Concentration (cells/mL) 
0 0.001 4.20E+06 
2 0.013 6.60E+06 
4 0.157 3.54E+07 
5 0.556 1.15E+08 
6 1.035 2.11E+08 
8 1.466 2.97E+08 
9 1.815 3.67E+08 
10 2.03 4.10E+08 
11 2.131 4.30E+08 
21 2.595 5.23E+08 
23 2.673 5.39E+08 
25 2.766 5.57E+08 
   
P.aeruginosa Cell Counting using Trial 2 Sample & y = 2E+8x+4E+6 
Incubation Time (hr) Optical Density (600nm) Concentration (cells/mL) 
0 0.018 7.60E+06 
2 0.019 7.80E+06 
3 0.020 8.00E+06 
4 0.021 8.20E+06 
5 0.023 8.60E+06 
6 0.033 1.06E+07 
7 0.062 1.64E+07 
8 0.210 4.60E+07 
9 0.475 9.90E+07 
10 1.146 2.33E+08 
11 0.646 1.33E+08 
21 2.513 5.07E+08 
24 2.722 5.48E+08 
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P.aeruginosa Cell Counting using Trial 3 Sample & y = 2E+8x+4E+6 
Incubation Time (hr) Optical Density (600nm) Concentration (cells/mL) 
0 0.015 7.00E+06 
2 0.018 7.60E+06 
3 0.020 8.00E+06 
4 0.024 8.80E+06 
5 0.045 1.30E+07 
6 0.175 3.90E+07 
7 0.405 8.50E+07 
8 0.990 2.02E+08 
9 1.299 2.64E+08 
10 1.170 2.38E+08 
11 1.135 2.31E+08 
21 2.408 4.86E+08 
24 2.611 5.26E+08 
   
P.aeruginosa Cell Counting using Trial 4 Sample & y = 2E+8x+4E+6 
Incubation Time (hr) Optical Density (600nm) Concentration (cells/mL) 
0 -0.359 -6.78E+07 
2 0.001 4.20E+06 
4 0.265 5.70E+07 
5 0.583 1.21E+08 
6 0.773 1.59E+08 
7 0.966 1.97E+08 
8 1.132 2.30E+08 
18 1.575 3.19E+08 
24 1.857 3.75E+08 
26 2.016 4.07E+08 
 
Figure 5 Related: 
C. albicans + Filastatin Trial 1 Growth Curve 8.18.2014 
Incubation 
Time (hr) 
OD Reading Control 
(600nm) 
OD Reading 
(600nm) 
Cell 
Concentration 
Control 
Cell 
Concentration 
0 -0.653 -0.655 0.00E+00 0.00E+00 
5 0.111 0.080 8.08E+05 5.14E+05 
6 0.298 0.196 2.52E+06 1.59E+06 
7 0.607 0.404 5.32E+06 3.48E+06 
8 0.919 0.637 7.94E+06 5.59E+06 
9 1.467 1.180 1.10E+07 9.64E+06 
10 1.708 1.514 1.19E+07 1.12E+07 
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11 1.929 1.804 1.26E+07 1.22E+07 
12 2.047 1.929 1.29E+07 1.26E+07 
23 2.214 2.105 1.34E+07 1.31E+07 
 
Figure 6 Related: 
P. aeruginosa + Filastatin Trial 1 Growth Curve 8.18.2014 
Incubation 
Time (hr) 
OD Reading Control 
(600nm) 
OD Reading 
(600nm) 
Cell Concentration 
Control 
Cell 
Concentration 
0 0.003 0.001 4.60E+06 4.20E+06 
2 0.231 0.092 5.02E+07 2.24E+07 
4 0.589 0.192 1.22E+08 4.24E+07 
5 1.035 0.573 2.11E+08 1.19E+08 
6 1.495 0.965 3.03E+08 1.97E+08 
7 1.802 1.541 3.64E+08 3.12E+08 
8 2.125 1.897 4.29E+08 3.83E+08 
18 2.59 2.201 5.22E+08 4.44E+08 
24 2.66 2.311 5.36E+08 4.66E+08 
26 2.723 2.458 5.49E+08 4.96E+08 
 
Figure 7 Related: 
 See Figure 5 Related 
Figure 8 Related: 
See Figure 6 Related 
Figure 17 Related: 
Trial 1 Glass Coupon Bioreactor 5.23.2014 
3E4 329µl/min for 17hrs @ 37°C 
Surface 
Surface 
Position 
Well 
Number 
OD Reading 
(590nm) 
Cell 
Concentration 
APTMS Glass 
Coupon 1 1A 0.219 1.80E+06 
APTMS Glass 
Coupon 2 2A 0.147 1.14E+06 
APTMS Glass 
Coupon 3 3A 0.123 9.20E+05 
APTMS Glass 
Coupon 4 4A 0.209 1.71E+06 
APTMS Glass 
Coupon 5 5A 0.151 1.18E+06 
Bare Glass Coupon 1 1B 0.164 1.30E+06 
Bare Glass Coupon 2 2B 0.108 7.80E+05 
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Bare Glass Coupon 3 3B 0.114 8.37E+05 
Bare Glass Coupon 4 4B 0.079 5.05E+05 
Bare Glass Coupon 5 5B 0.102 7.23E+05 
     
Trial 2 Glass Coupon Bioreactor 7.23.2014 
3E4 329µl/min for 17hrs @ 37°C 
Surface 
Surface 
Position 
Well 
Number 
OD Reading 
(590nm) 
Cell 
Concentration 
APTMS Glass 
Coupon 1 1A 0.245 2.04E+06 
APTMS Glass 
Coupon 2 2A 0.368 3.15E+06 
APTMS Glass 
Coupon 3 3A 0.560 4.90E+06 
APTMS Glass 
Coupon 4 4A 0.559 4.89E+06 
APTMS Glass 
Coupon 5 5A 0.494 4.30E+06 
Bare Glass Coupon 1 1B 0.469 4.07E+06 
Bare Glass Coupon 2 2B 0.253 2.11E+06 
Bare Glass Coupon 3 3B 0.223 1.84E+06 
Bare Glass Coupon 4 4B 0.271 2.27E+06 
Bare Glass Coupon 5 5B 0.323 2.75E+06 
 
Figure 9 Related: 
Average OD Bioreactor Trial Data Comparison 
Trial 1 2 
APTMS 0.17 0.445 
Bare Glass 0.113 0.308 
 
Figure 19 Related: 
Trial 1 Bioreactor (estimated cell count) 7.14.2014 
3E5 329µl/min for 17hrs @ 37°C 
Surface Surface Position Well Number OD Reading (590nm) 
APTMS Glass Coupon 1 1A 0.061 
APTMS Glass Coupon 2 2A 0.055 
APTMS Glass Coupon 3 3A 0.044 
APTMS Glass Coupon 4 4A 0.039 
APTMS Glass Coupon 5 5A 0.049 
Bare Glass Coupon 1 1B NA 
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Bare Glass Coupon 2 2B NA 
Bare Glass Coupon 3 3B NA 
Bare Glass Coupon 4 4B NA 
Bare Glass Coupon 5 5B NA 
 
Figure 10 Related: 
Average OD Trial 1 Bioreactor 
Mean APTMS 0.050 
 
Figure 11 Related: 
Average Cell Concentration Bioreactor Trial Data Comparison 
Trial 1 2 
APTMS 1.35E+06 3.85E+06 
Bare Glass 8.29E+05 2.61E+06 
Standard Deviation 261660 623400 
 
 
 
 
 
 
 
 
 
 
 
 
